Underdosing in Patients With Cancer and Obesity: A Thing of the Past?
New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.
Urologic Cancers News
UROLOGIC CANCER ADVISOR
Urologic Cancers News
Two-Drug Regimen Offers Better Health-Related Quality of Life in Advanced Renal Cell Carcinoma
The combination of lenvatinib and pembrolizumab improved health-related quality of life.
Telaglenastat Fails to Improve Outcomes in Previously Treated Metastatic RCC
Adding telaglenastat to cabozantinib does not significantly prolong PFS compared with placebo plus cabozantinib in patients with mRCC whose disease progressed after 1 or 2 prior lines of systemic therapy.
Combo Continues to Show Superior Efficacy vs Sunitinib in Advanced Clear Cell Renal Cell Carcinoma
Pembrolizumab plus axitinib improved progression-free and overall survival.
Pembrolizumab After RCC Surgery: Potential New Standard of Care
In the randomized phase 3 KEYNOTE-564 trial, pembrolizumab treatment after nephrectomy for clear cell RCC was associated with a 32% decreased risk of cancer recurrence or death compared with placebo.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
Understanding Adverse Effects Associated With Immune-Based Combination Therapies for Metastatic Renal Cell Carcinoma
A meta-analysis of phase 3 randomized control trials sought to identify the TRAEs associated with 7 therapeutic regimens for the treatment of mRCC.
High Body Mass Index Is a Risk Factor for Gallbladder and Biliary Tract Cancer Mortality
A decrease in obesity rates may reduce the burden of gallbladder and biliary tract cancer worldwide, according to the results of a study.
Obesity Paradox in Renal Cell Carcinoma: Why Do Patients Who Are Obese Have Improved Survival?
A review of retrospective data sought to better understand the relationship between obesity and survival in renal cell carcinoma.
Active Surveillance Deemed “Justifiable” Option for Metastatic Renal Cell Carcinoma
For real-world patients with mRCC, active surveillance may be a worthwhile alternative to immediate systemic therapy.
Ureteroscopic Biopsy in UTUC May Increase Risk of Intravesical Recurrence
Compared with no ureteroscopy or percutaneous biopsy, ureteroscopic biopsy in patients with upper tract urothelial carcinoma was significantly associated with a 40% increased risk for intravesical recurrence of disease.
Complete TURBT Before Neoadjuvant Chemotherapy Improves MIBC Outcomes
Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for muscle-invasive bladder is associated with improved overall and cancer-specific survival, a study found.
Local Salvage Therapy Effective for Local, Regional Recurrence of RCC
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Prophylactic Ureteral Stenting Linked to Upper Tract Urothelial Carcinoma
In current urological practice, clinicians decide whether to place a ureteral stent or nephrostomy, but evidence-based treatment guidance is needed.
Trodelvy Gets Accelerated Approval for Urothelial Cancer
The accelerated approval was based on data from the multicenter, open-label, phase 2 TROPHY study.
Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Seminal Vesicle-Sparing in Radical Cystectomy Shown to Improve Outcomes
Seminal vesicle-sparing radical cystectomy improved functional results over a median of 64 months without compromising oncologic outcomes, according to investigators.
Oncologic Outcomes, Costs of High-Risk NMIBC Need to Improve
High-risk NMIBC progression more than doubled healthcare costs over 5 years compared with no progression, a study found.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...